Recombinant RSV-F Post Fusion

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection and hospitalization in infants¹. RSV F protein is a type I integral membrane protein essential for viral membrane fusion that is highly conserved among isolates of RSV A and B subgroups and is the primary target for RSV antiviral drug development². RSV F protein is synthesized as a 574 amino acid inactive precursor, assembled into a trimer, post-translationally modified, and then cleaved during activation for membrane fusion to produce F1, F2, and intervening peptide pep27². When functional F protein trimer in the virion membrane is triggered, F protein merges virus and host-cell membranes using the difference in folding energy between its pre-fusion (pre-F) and post-fusion (post-F) forms³. During infection, RSV-neutralizing antibodies target epitopes that reside primarily on the pre-F conformation^{3, 4}, particularly antigenic site Ø on the apex of pre-F, which is highly sensitive to neutralization and exclusive to the pre-F conformation⁵. However, some neutralizing sites are common between pre- and post-F, including Site II, which binds the antibodies Motavizumab, Palivizumab, and 47F, as well as Site IV which binds 101F⁶. Additionally, the RSV F post-fusion trimer elicits high titers of neutralizing antibody when administered to mice and cotton rats⁷. Both pre- and post-F protein conformations are targets of RSV vaccine development⁸.

Recombinant RSV-F Post Fusion Protein is provided under an intellectual property license from the National Institutes of Health (NIH). The purchase of this protein conveys to the buyer the non-transferable right to use the purchased protein for research use only (RUO). As this protein is protected by the intellectual property rights of the NIH, the buyer of this protein (academic or commercial) is expressly prohibited from using the protein or any derivative in any commercial (revenue generating) activity. Such activities may include, but are not limited to, manufacturing, services, therapeutics, diagnostics, prophylactics or resale (including RUO).

Viral

P03420

Lyophilized

~180k Non-reducing conditions

60.5k monomer 181.5k Trimer

Lyophilized from PBS + 5% Trehalose

Reconstitute at 0.1-1 mg/ml using filtered deionized water. Gently mix by vortexing and/or inversion until fully dissolved. Centrifuge if necessary.

This lyophilized protein is stable for twelve months when stored at -20°C to -70°C. After aseptic reconstitution, this protein may be stored for one month at 2°C to 8°C or for three months at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Ambient

Viral

Research Use Only

1. Hammitt LL, Dagan R, Yuan Y, et al. N Engl J Med. 386(9):837-846. 2022.
2. McLellan JS, Ray WC, Peeples ME. Curr Top Microbiol Immunol. 372:383-104. 2013.
3. McLellan JS, Chen M, Joyce MG, et al. Science. 342(6158):592-598. 2013.
4. Magro M, Mas V, Chappell K, et al. Proc Natl Acad Sci U S A. 109(8):3089-3094. 2012.
5. Crank MC, Ruckwardt TJ, Chen M, et al. Science. 365(6452):505-509. 2019.
6. Steff AM, Monroe J, Friedrich K, et al. Nat Commun. 8(1):1085. 2017.
7. Swanson KA, Settembre EC, Shaw CA, et al. Proc Natl Acad Sci U S A. 108(23):9619-9624. 2011.
8. Graham BS, Modjarrad K, McLellan JS. Curr Opin Immunol. 35:30-38. 2015.
9. Espeseth AS, Cejas PJ, Citron MP, et al. NPJ Vaccines. 5(1):16. 2020.